1. Introduction.
Pulmonary embolism (PE ) and Deep vein thrombosis (DVT ) continues to be a cause of signicant morbidity and mortality which is also third
1
leading cardiovascular cause of death . If not treated properly it also leads to chronic pulmonary hypertension and cor pulmonale . Once DVT is
diagnosed treatmet is required and consist of oral anticoagulation and inferior vena cava interruption via lter placement in patients with
contraindication for anticoagulation treatment.
In 2003 ,the U.S .Food and Drug Administration (FDA ) cleared retrievable inferior vena cave lters (rIVCFs) for clinical use , after that its uses
exponentially increases . In parallel with these trends ,there has been growing awareness of device –related complication including fracture ,
penetration to adjuscent structure , migration , thrombosis and some time embolisation of fractured segment in heart that leads to cardiac
2 3
peforation , arrhythmia and death . In response , the FDA released safety communication in 2010 and 2014 advocating immediate retrieval of
4
lter once mechanical prophylaxis was no longer uses .However retrieval of lter remained rare with rates reported as low as 8.5 %. . Once lter
remain in place for long duration, normal standard snare retrieval technique usually not work and alternative techniques like , Sling technique ,
5 Excimer laser and Endobronchial forcep supported methods can be used . But prolong duration of lter implantion always associated with less
chance of lter retrieval and associated with multiple complication .